pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,160 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT967Endpoints742BioPharma Dive283BioSpace181Fierce Biotech172onclive165globenewswire health73raps
therapy area
allOncology5618Rare Disease1251Cardiology1054Hematology939Immunology929Vaccines816Pulmonology
  • Veradermics reports first positive efficacy data for oral minoxidil in women with pattern hair loss
    Veradermics announced that its oral formulation of minoxidil demonstrated positive efficacy in a mid‑stage trial involving women with pattern hair loss. The results mark the company's first effica…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Mwyngil Therapeutics launches obesity program that avoids GLP-1 pathway
    Mwyngil Therapeutics, a newly formed biotech startup, is pursuing obesity treatments that do not target the GLP-1 receptor, a pathway that has dominated recent weight-loss drug development. CEO Lu…
    STAT · 1mo agoNeutral↗ source
← prev
page 34 of 87
next →
65
fda recalls41
fda medwatch32
fda press25
780
Psychiatry & CNS690
Ophthalmology345
Pain342
Endocrinology & Metabolism340
Infectious Disease331
  • Scientists and stakeholders overwhelmingly oppose White House grantmaking overhaul, analysis finds
    Researchers at the University of North Carolina at Chapel Hill, working with STAT, examined a flood of public comments on a White House proposal to revamp the federal "Uniform Guidance" that govern…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Senator Lindsey Graham's death from aortic dissection spotlights need for better screening
    Senator Lindsey Graham died at age 71 after suffering an aortic dissection, drawing public attention to this rare but deadly condition. An aortic dissection occurs when the body's main blood vesse…
    STAT · 1mo agoNegative↗ source
  • FTC settlement forces CVS Caremark to change insulin pricing, could save US patients $8.5 billion
    The Federal Trade Commission announced it has settled a lawsuit against CVS Caremark, one of the nation's largest pharmacy benefit managers, over claims the company inflated insulin prices and rest…
    STAT · 1mo agoRegulatoryPositive↗ source
  • 340B Drug Discount Program sales hit $100 billion in 2025, up 22.8% year over year
    The Health Resources and Services Administration reported that purchases under the 340B discount program reached $100 billion in 2025, a 22.8% rise from 2024. Expensive medicines made up a growing…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • Celcuity receives FDA approval for Revtorpyk breast cancer therapy
    Celcuity, a small public biotech, announced that the U.S. Food and Drug Administration has cleared its drug Revtorpyk for use in breast cancer patients when combined with fulvestrant. The approval…
    Endpoints · 1mo agoApprovalPositive↗ source
  • Bipartisan Bill to Limit US Biotech Deals with China Remains in Limbo
    A bipartisan bill introduced in the House seeks to bar U.S. biotechnology firms from entering into collaborations or licensing agreements with Chinese companies. The proposal sparked strong reacti…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Live webcast examines why biotech IPOs are gaining momentum again
    Drew Armstrong, executive editor at Endpoints News, announced a live webcast scheduled for July 15 at 12 p.m. ET. The session will feature Parabilis CEO Mathai Mammen and Kailera CEO Ron Renaut, al…
    Endpoints · 1mo agoPositive↗ source
  • Cyclospora infections hit record high in 2026, Michigan officials suspect lettuce as source
    Infections caused by the parasite Cyclospora have surged to a record level in 2026, with more than 30 states reporting cases that now exceed the previous U.S. high of about 4,700 set in 2019. The…
    STAT · 1mo agoNegative↗ source
  • STAT+: Top Democrats question RFK Jr.’s health care advisory panel
    Democratic senators question presence of Trump donors, Tony Robbins on health care advisory panel.
    STAT · 1mo ago↗ source
  • STAT+: Hospital chain HCA warns of lower profits as more patients go uninsured
    It's an early indicator of the fallout from the end of extra ACA subsidies.
    STAT · 1mo ago↗ source
  • STAT+: Anthropic’s Claude Science is coming for Kendall Square
    AI still has the potential to do more than reduce corporate head counts. Watch out, Kendall Square.
    STAT · 1mo ago↗ source
  • A health tech workaround is under fire
    At the end of June, a settlement between California’s attorney general and bankrupt clinic company Carbon Health put the digital health industry on notice. The state’s Justice Department accused Ca…
    Endpoints · 1mo ago↗ source
  • Majority of new Ebola cases in eastern Congo are from unknown chains, as outbreak outpaces response
    The Ebola outbreak in eastern Congo “continues to outpace the response efforts,” the WHO’s emergencies chief said on Tuesday after returning from a trip to one of the worst hit…
    STAT · 1mo ago↗ source
  • Erasca's $550M offering; Summit sells an antibiotic
    Plus, news about subcutaneous Leqembi, WuXi AppTec and Q32 Bio. 📊 Erasca targets $550M for KRAS drugs: The biotech's public offering came after it shared a small ...
    Endpoints · 1mo ago↗ source
  • STAT+: Akero team, backed by Fairmount, launches new immunology company
    FDA approves injectable Leqembi, another post-Makary reversal, and other biotech news from The Readout
    STAT · 1mo ago↗ source
  • Chai Discovery gets $400M, tripling valuation from seven months ago
    Chai Discovery, one of the hottest startups in the AI-generated drug discovery landscape, has corralled $400 million in a Series C that triples its paper value from its last round of financing. In…
    Endpoints · 1mo ago↗ source
  • The risk of refusing a newborn’s vitamin K shot
    Health care workers on strike at Ebola treatment center, how to tackle the U.S. alcohol epidemic, and more Morning Rounds news
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more
    A U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching ​an agreement allowing Teva to market a generic ‌version of Forteo
    STAT · 1mo ago↗ source
  • Biogen's tau drug reports mixed Alzheimer's results, as low dose performs better
    LONDON — Biogen's attempt to treat Alzheimer's by going after a protein that forms toxic tangles in the brain showed some of the strongest proof yet that it could slow dementia. But the results wer…
    Endpoints · 1mo ago↗ source
  • STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows
    An experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.
    STAT · 1mo ago↗ source
  • Draig nets $65M to advance depression drug aimed at rebuilding synapses
    Draig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA re…
    Endpoints · 1mo ago↗ source
  • Genetic medicine startup Lyora launches with programs from Editas, Biogen
    Lyora Therapeutics will try to revive several early-stage genetic eye disease programs previously held by Editas Medicine and Biogen. The biotech was co-founded by Luk Vandenberghe and Eric Pierce,…
    Endpoints · 1mo ago↗ source
  • AstraZeneca to take rights to Dizal's lung cancer pill Zegfrovy
    AstraZeneca is set to pay Dizal Pharmaceutical, which it part-owns, $600 million upfront for worldwide development and sales rights to the lung cancer drug Zegfrovy. The UK pharma said Tuesday that…
    Endpoints · 1mo ago↗ source